Fuda Cancer Hospital
Fuda Cancer Hospital
Китай, Гуанчжоу
| Китай | Туреччина | Україна | |
| Томотерапія | від $17,500 | від $12,000 | від $12,000 |
| Роботизированная система Да Винчи | від $24,500 | від $9,500 | від $8,000 |
| Резекція товстого кишечника | від $16,800 | від $14,000 | від $2,600 |
| Променева терапія при раку кишечника | від $10,500 | від $5,800 | від $3,458 |
| Нано-ніж | від $22,500 | від $9,500 | від $5,000 |
Професор Лю Шісінь, MD, PhD, — керівник напряму Центру онкології. Колишній президент Онкологічної лікарні провінції Цзілінь і директор Інституту досліджень профілактики та лікування раку. Професор другого рівня, керівник докторантів. Відзначений Спеціальною урядовою надбавкою Держради, нагородою «Національно відомий лікар (видатний внесок)» (4-й випуск) і званням «Зразок медичної етики».
Спеціалізується на комплексній діагностиці та лікуванні злоякісних пухлин, з акцентом на прецизійну променеву терапію новоутворень грудної клітки та черевної порожнини. Володіє методиками IMRT, VMAT і SBRT при раку легені, стравоходу, молочної залози та прямої кишки.
Займає керівні посади: заступник голови CMA Radiation Oncology, CACA Radiotherapy та CACA Particle Therapy; член Постійного комітету CSCO і заступник голови CSCO Radiation Oncology Expert Committee; заступник голови CPAM Radiation Oncology та член Постійного комітету CSMEA. Очолює відділення променевої онкології Медичної асоціації провінції Цзілінь. Член редколегій Chinese Journal of Radiation Oncology та Practical Journal of Cancer.
The 5-year relative survival rate for colon cancer in China is approximately 58% to 62%. Early-stage detection yields high survival rates between 85% and 96%. Outcomes correlate strongly with geographic location and the use of curative radical surgery over palliative care.
Bookimed Expert Insight: Patient volume serves as a critical quality indicator in China. Fuda Cancer Hospital serves over 30,000 international patients. Xiamen Humanity Hospital manages around 1,000,000 patients annually. High-volume centers often provide faster access to specialized technologies like NanoKnife and CyberKnife M6 for complex cases.
Patient Consensus: Patients emphasize choosing tier-3 hospitals in major cities to ensure Western-level outcomes. Many recommend using specialized apps to track real-time follow-up statistics and manage post-operative care.
Colon cancer treatment in China focuses on surgical resection and minimally invasive techniques. Hospitals utilize laparoscopy for over 56% of cases to ensure faster recovery. Advanced centers combine specialized surgery with chemotherapy, targeted therapies, or immunotherapy based on genetic markers like KRAS and MSI status.
Bookimed Expert Insight: While most centers follow standard protocols, Fuda Cancer Hospital differentiates itself by applying over 10 types of minimally invasive therapies. Their focus on cryosurgery and vascular interventional therapy provides alternatives for patients who cannot tolerate aggressive chemotherapy after 30,000+ international cases.
Patient Consensus: Patients note that while surgery is the standard first-line approach, access to advanced diagnostics like PD-L1 testing often depends on whether you are in a major city center.
Stage 4 colon cancer is treatable in China through advanced multidisciplinary protocols in specialized oncology centers. Medical facilities utilize radical resection, NanoKnife ablation, and HIPEC to manage metastatic disease. Integration of modern drug therapies with traditional supportive care helps extend survival and maintain patient quality of life.
Bookimed Expert Insight: Patients seeking treatment in China should prioritize JCI-accredited facilities in major hubs like Guangzhou. Data shows clinics like Fuda Cancer Hospital focus on minimally invasive therapies like cryosurgery and NanoKnife. These options serve as alternatives for those who may not tolerate standard high-dose chemotherapy well.
Patient Consensus: Patients note that getting imaging reviewed at a major Tier-1 city hospital is essential for accurate staging. Many emphasize that while costs for multimodal therapy are significant, the expertise in top academic centers is comparable to Western standards.
Traditional Chinese Medicine (TCM) serves as a supportive integrative therapy for colon cancer in China. It combines herbal formulas, acupuncture, and lifestyle practices with surgery or chemotherapy to improve quality of life. These protocols focus on reducing treatment side effects and strengthening the immune response.
Bookimed Expert Insight: Integrative care in China often combines ancient practices with advanced technology at the same facility. For example, Jinshazhou Hospital of Guangzhou University of Chinese Medicine offers CyberKnife M6 radiosurgery alongside traditional protocols. Our data shows these specialized centers provide comprehensive packages around $7,900 that include medical consultations and hospital stays.
Patient Consensus: Patients note that IV herbal drips and acupuncture are often provided directly in the hospital ward. They emphasize using these therapies to manage pain and speed up wound healing after a colon resection.
China provides specialized treatments for inoperable tumors including cryosurgery, NanoKnife, and advanced immunotherapy. Facilities like Fuda Cancer Hospital are Joint Commission International (JCI) accredited. They specialize in treating late-stage cancer using over 10 types of minimally invasive therapies to manage complex cases.
Bookimed Expert Insight: While many countries focus on single-modality treatments for late-stage cases, specialized Chinese centers often combine cryosurgery with vascular intervention. Fuda Cancer Hospital has utilized this combined approach for over 30,000 patients from 100 countries. This high volume of international cases suggests a robust infrastructure for managing complex, multi-stage treatment protocols that may not be available elsewhere.
Patient Consensus: Patients with advanced tumors note that while treatments like CyberKnife can shrink inoperable lesions, the physical toll and fatigue are significant. Many emphasize the importance of verifying trial data before starting newer immunotherapies due to varying clinical outcomes.